Vaccination with MIP or Pgp3 induces cross-serovar protection against chlamydial genital tract infection in mice

Luan, Xiuli; Peng, Bo; Li, Zhongyu; Tang, Lingli; Chen, Chaoqun; Chen, Lili; Wu, Haiying; Sun, Zhi; Lu, Chunxue

doi:10.1016/j.imbio.2018.11.009

Cited by 8 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first causes genital chlamydia infection, and the second ocular infection, trachoma but are similar in pathology and affecting the immune system. [37][38][39] An effective human chlamydial vaccine would have public health benefits in both HICs and LMICs. The greatest benefits will be in LMIC settings, where lack of medical infrastructure and resources preclude chlamydia screening programs and the disease burden is high.…”

Section: Discussionmentioning

confidence: 99%

Identifying the gaps in human and veterinary chlamydia vaccine development

et al. 2020

View full text Add to dashboard Cite

Background: Chlamydia infections in humans and animals pose a significant burden on health systems worldwide. While widespread screening, adequate treatment, and prevention programs are helpful to increase awareness and improve screening rates, infection rates are rising. A vaccine is necessary to slow increasing rates, manage negative consequences, and prevent possible antibiotic resistance. We present the current landscape regarding the innovations for commercial vaccine development in a “one-health” context.Methods: We developed a unique dataset containing data of patent documents intended for human and veterinary use, and clinical trials in order to provide a detailed description of the global chlamydia vaccine developments.Results: Analysis of patents and clinical trials intended for human use presented a vaccine field that is underdeveloped, with no commercial human chlamydia vaccine available, and two potential candidates in a phase 1 clinical trial. Comparing innovations concerning chlamydia vaccine developments for both human and veterinary patents, it was clear that these fields are very different and independent of each other. The field is small, and certain companies and researchers show repeated interest. Partnerships among applicants and those involved in chlamydia vaccine innovation would be an important step to take towards innovating and developing an effective vaccine.Conclusions: We have shown that North America is considered, by patent application, to hold the most potential for a chlamydia vaccine, specifically against the Chlamydia trachomatis strain. A new vaccine is likely to be a subunit vaccine with components of the major outer membrane protein antigen.

show abstract

Section: Discussionmentioning

confidence: 99%

Identifying the gaps in human and veterinary chlamydia vaccine development

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The recombinant plasmid pGEX6p/pgp3 was transformed into Escherichia coli XL-1 Blue to express GST-tagged C. trachomatis strain D/UW-3/CX protein Pgp3, as described previously ( 17 ). GST-Pgp3 was purified using glutathione-conjugated agarose beads and cleaved using a precision protease (Amersham Pharmacia Biotech, Inc., Piscataway, NJ, USA) to remove the GST tag.…”

Section: Methodsmentioning

confidence: 99%

“…Vaginal swabs were taken every 4 days until 28 days after infection to monitor chlamydial shedding in the lower genital tract of the mice. Each swab sample was diluted appropriately and used to infect HeLa 229 monolayers as described previously ( 17 , 22 ). After 24 h of incubation, inclusion bodies in the culture were visualized by immunofluorescence assay and counted under a microscope.…”

Section: Methodsmentioning

confidence: 99%

“…First, the entire genital tract, including the vagina, cervix, uterine horn, oviduct, and ovary, was checked for swelling, inflammation, and adhesion changes in situ . Under the naked eye, the hydrosalpinx of the oviduct was obvious, and the severity was scored as reported previously ( 17 , 23 ). Briefly, the ovary of each mouse was used as a size reference: 0, no hydrosalpinx; 1, hydrosalpinx suspicious, not sure; 2, hydrosalpinx is clear and its size is smaller than that of the ovary; 3, similar size to that of the ovary; and 4, larger than the ovary.…”

Section: Methodsmentioning

confidence: 99%

“…The subcutaneous immunization of C57BL/6N mice with recombinant Pgp3 protein induced a significantly lower organism burden in the lungs following C. muridarum airway infection ( 16 ). BALB/c mice intranasally immunized with recombinant Pgp3 protein purified from chlamydial serovar D exhibited cross-serovar protection against C. muridarum genital tract infection ( 17 ). Furthermore, immunization with Chlamydia psitaci CPSIT_P7, homologous of C. trachomatis Pgp3 with 70% protein sequence identity, provided partial protection against C. psitaci lung infection in BALB/c mice ( 18 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of Pgp3 vaccination for Chlamydia urogenital tract infection depends on its native conformation

et al. 2022

Self Cite

View full text Add to dashboard Cite

Urogenital tract infections with Chlamydia trachomatis have frequently been detected among patients diagnosed with sexually transmitted infections, and such infections lead to inflammatory complications. Currently, no licensed chlamydial vaccine is available in clinical practice. We previously reported that immunization with recombinant C. trachomatis plasmid-encoded virulence factor Pgp3 provided cross-serovar protection against C. muridarum genital tract infection. Because Pgp3 is a homotrimer and human antisera only recognize the trimeric form of Pgp3, we compared the effects of the native conformation of Pgp3 (trimer) and heat-denatured Pgp3 (monomer) to determine whether the native conformation is dispensable for the induction of protective immunity against chlamydial vaginal challenge. Both Pgp3 trimer and monomer immunization induced corresponding specific antibody production, but only trimer-induced antibody recognized endogenous Pgp3, and trimer-immunized mouse splenocytes showed the highest IFN-γ production upon restimulation with the chlamydial elementary body or native Pgp3 in vitro. Importantly, only Pgp3 trimer-immunized mice showed shortened lower genital tract chlamydial shedding and decreased upper genital tract pathology. Thus, Pgp3-induced protective immunity against Chlamydia urogenital tract infection is highly dependent on the native conformation, which will guide the design of Pgp3-based polypeptides and multi-subunit chlamydial vaccines.

show abstract

A novel chimeric recombinant FliC-Pgp3 vaccine promotes immunoprotection against Chlamydia muridarum infection in mice

Zhao,

Wang,

2024

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

Vaccination with MIP or Pgp3 induces cross-serovar protection against chlamydial genital tract infection in mice

Cited by 8 publications

References 32 publications

Identifying the gaps in human and veterinary chlamydia vaccine development

Identifying the gaps in human and veterinary chlamydia vaccine development

Efficacy of Pgp3 vaccination for Chlamydia urogenital tract infection depends on its native conformation

A novel chimeric recombinant FliC-Pgp3 vaccine promotes immunoprotection against Chlamydia muridarum infection in mice

Contact Info

Product

Resources

About